BRKR — Bruker Corporation

Bruker Corporation Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q2 2026 reported revenues were $839 million, a 5.2% increase year-over-year. Organic growth was 2.8%, or 3.4% excluding U.S. tariff refunds. M&A contributed 1.5%, and constant currency growth was 4.3%.
• Margins: Non-GAAP gross margin increased to 52.1%, up 350 basis points year-over-year. Non-GAAP operating margin was 14.1%, up 510 basis points.
• Earnings: Non-GAAP diluted EPS was $0.49, a 53% increase from $0.32 in Q2 2025. GAAP diluted loss per share was $0.41, impacted by a $135 million goodwill impairment charge.
• First Half Performance: H1 2026 revenues were $1.66 billion, up 3.9% year-over-year, with organic revenue decline of 0.8%.

2. Strategic Updates and Business Highlights

• Organic Growth: The Scientific Instruments segment achieved 10% organic bookings growth, with biopharma bookings up over 20%. Strong demand was noted in semiconductor tools and energy research technologies, both exceeding 50% organic order growth.
• New Operating Structure: Bruker reorganized into four groups: Bruker Biosystems, Bruker Nano, Bruker Microbiology and Infection Diagnostics (BMID), and Bruker Energy and Supercon Technologies (BEST). This aims to enhance agility and innovation.
• Cost Savings: Continued focus on cost reductions, targeting $140 million in annualized savings for 2026, with additional savings expected from the new structure.

3. Forward Guidance and Outlook

• Fiscal Year 2026 Guidance: Expected revenue of $3.54 billion to $3.57 billion, representing 3% to 4% growth. Organic growth is anticipated at 1% to 2%. Non-GAAP EPS guidance remains at $2.10 to $2.15, reflecting a 15% to 17% increase.
• Q3 Expectations: Anticipated flat to slightly up organic revenue due to a $20 million revenue shift from Q3 to Q4. Margins expected to decrease slightly sequentially due to this shift and reduced tariff benefits.

4. Bad News, Challenges, or Points of Concern

• Weak U.S. Academic Orders: Continued weakness in U.S. academic and government orders, down over $15 million year-over-year, remains a significant concern.
• Goodwill Impairment: A $135 million noncash goodwill impairment charge reflects ongoing challenges in the automation and spatial biology segments.
• Currency Headwinds: A stronger U.S. dollar is expected to create a headwind in Q3, impacting revenue growth.

5. Notable Q&A Insights

• Tariff Refunds: Clarified that tariff refunds impacted revenue growth negatively but contributed positively to margins. Future expectations for these refunds have been baked into guidance.
• Semiconductor Demand: Strong order growth in the semiconductor sector is expected to sustain through 2027, although delivery times may lag due to customer readiness.
• Visibility and Order Dynamics: Bruker is experiencing improved visibility in bookings, particularly in deep tech areas, but acknowledges the delayed revenue recognition due to longer delivery times.
• Regional Performance: European aca/gov orders showed strong growth, contrasting with declines in the U.S., indicating potential shifts in market dynamics.

This summary encapsulates the key points from Bruker's Q2 2026 earnings call, highlighting financial performance, strategic initiatives, outlook, challenges, and insights from the Q&A session.